Updated Results from Phase 2 Clinical Trial of KRX-0401 in
Combination with Capecitabine for the treatment of Metastatic Colon
Cancer to be Presented on Sunday, January 24, 2010
NEW YORK, Jan 21 /PRNewswire-FirstCall/ — Keryx
Biopharmaceuticals,…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor = [...]
THOUSAND OAKS, Calif., Jan. 21 /PRNewswire-FirstCall/ — Amgen
(NASDAQ: AMGN) today announced that detailed
results from two pivotal Phase 3 studies evaluating Vectibix®
(panitumumab) in combination with chemotherapy for the first…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor = “FFFFFF”; channel = [...]
Updated results from Phase 2 clinical trial of perifosine in
combination with capecitabine for the treatment of metastatic colon
cancer to be presented on Sunday, January 24, 2010
QUEBEC CITY, Jan. 21 /PRNewswire-FirstCall/ — AEterna Zentaris
Inc….
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor [...]
- Primary and Secondary Endpoints Not Met -
DURHAM, N.C.–(BUSINESS WIRE)–Jan 21, 2010 – Inspire
Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today that its Phase
3 clinical trial (Trial 03-113) of PROLACRIA™ (diquafosol
tetrasodium…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor = “FFFFFF”; channel [...]
ROCKLAND, Mass., Jan. 21 /PRNewswire/ — EMD Serono, an
affiliate of Merck KGaA, Darmstadt, Germany, announced today the
online publication of the results from the CLARITY(1) Phase III
trial using Cladribine Tablets (EMD Serono’s…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor = “FFFFFF”; [...]
* Successful conclusion of first clinical trial for GLPG0187 *
Plans to initiate clinical trial in cancer patients this year
Mechelen, Belgium; 19 January 2010 – Galapagos NV (Euronext:
GLPG) announced results from the first-in-human trial…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor [...]
THE WOODLANDS, Texas, Jan. 20 /PRNewswire-FirstCall/ –
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a
biopharmaceutical company focused on discovering breakthrough
treatments for human disease, obtained positive results from a
recently completed…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor = “FFFFFF”; channel = “none”; [...]
* Combined data from TRANSFORMS and FREEDOMS studies show
significant efficacy in reducing relapses, disability progression
and MRI lesions in MS
* In FREEDOMS, FTY720 0.5 mg dose reduced the risk of 3-month
and 6-month confirmed disability…
linkscolor = “000000″; highlightscolor = “888888″; backgroundcolor [...]